Disclaimer: This article is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Individual results may vary. Always consult your healthcare provider before starting, stopping, or switching any prescription medication. This article contains no affiliate links or product promotion.
The Short Answer
Since January 2026, Wegovy has existed in two FDA-approved forms: the original once-weekly injection and a once-daily tablet, approved by the FDA on December 22, 2025. Both contain the same active ingredient, semaglutide, and both require a prescription. The tablet isn't a simplified version of the injection — the dose is different, how your body absorbs it is different, and the evidence behind each comes from separate clinical trials of different sizes. Switching between them follows specific FDA-labeled steps, and it's a decision for your prescriber, not a do-it-yourself swap.
What Changed in Late 2025
For most of Wegovy's history, it only existed as a self-administered subcutaneous injection, taken once a week. That changed when the FDA approved an oral semaglutide tablet under the same Wegovy brand, which reached U.S. pharmacies in early January 2026 — the first oral GLP-1 medication approved specifically for chronic weight management in the United States.
Per the FDA label, both forms are approved for the same core population: adults with obesity, or adults with overweight who have at least one weight-related health condition, used alongside a reduced-calorie diet and increased physical activity. Both also carry an indication for reducing cardiovascular risk in adults with established heart disease. The indications match — the delivery method and the supporting evidence base do not.
Same Active Ingredient, Different Dose — Here's Why
Both forms deliver semaglutide, a GLP-1 receptor agonist that mimics a hormone your body produces naturally — one that signals fullness to your brain and slows stomach emptying. That mechanism doesn't change based on delivery method.
What does change is the dose. The injection's usual maintenance dose is 2.4 mg once weekly. The tablet's maintenance dose is 25 mg once daily. That's not a sign the pill is a stronger drug — oral semaglutide is absorbed far less efficiently through the digestive tract than injected semaglutide, so the labeled dose has to be much higher to reach a comparable effect. The two doses aren't interchangeable milligram-for-milligram, which is exactly why switching between them follows a specific FDA-defined protocol rather than simple math.
How the Tablet Has to Be Taken
The injection has no meal-timing rules. The tablet does, and skipping them can reduce how much of the drug your body actually absorbs. Per the FDA label:
- Take it on an empty stomach, first thing in the morning
- Swallow the tablet whole, with no more than a small amount of water
- Wait at least 30 minutes before eating, drinking anything else, or taking other oral medications
If convenience is the main draw of the tablet, this is the tradeoff to weigh honestly: the injection removes a weekly decision, the tablet adds a daily routine with real timing constraints.
Switching Between Forms: What the FDA Label Actually Specifies
The FDA label lays out switching in both directions, and they're not mirror images of each other:
- Injection to tablet: one week after the last 2.4 mg injection dose, start the 25 mg tablet once daily
- Tablet to injection: the day after the last 25 mg tablet dose, start the 2.4 mg injection once weekly — no week-long gap required going this direction
- If the 25 mg tablet isn't tolerated, the label specifies considering a switch to the 1.7 mg injection dose, not the full 2.4 mg maintenance dose
None of this is something to self-manage. A prescriber needs to confirm which direction applies, what dose to start at, and whether your current health status and medications change any of it.
What the Trials Actually Showed
This is the part most comparison content oversimplifies, so here's the honest version. The tablet's approval rested primarily on the OASIS 4 trial: 307 adults with obesity or overweight, 64 weeks, average weight loss of 13.6% on the tablet versus 2.2% on placebo. The injection's approval rested on the STEP 1 trial: 1,961 adults, 68 weeks, average weight loss of 14.9% versus 2.4% on placebo, published in the New England Journal of Medicine.
Those numbers look close, and directionally the results are comparable — but this is not a head-to-head trial. OASIS 4 and STEP 1 enrolled different people at different times under different trial designs. STEP 1 also has roughly six times the sample size and years more follow-up data behind it across the broader GLP-1 research literature. Treat the percentages as “both show meaningful average weight loss in their own trials,” not as proof that any individual person would lose the same amount on either form.
Side Effects
Reported side effects for the tablet fall in the same general category as the injection — primarily gastrointestinal, including nausea, diarrhea, constipation, and stomach discomfort, especially during dose increases. Don't assume identical frequency or severity between the two forms; that depends on your own health history, and it's a direct question for your prescriber.
A Comparison Worksheet for Your Own Conversation
Before you bring this up with a prescriber, it helps to separate what's actually established from what still needs a professional answer:
- Population the evidence covers: ask whether the trial data for each form reflects people with a health profile similar to yours
- Route and exact dose: confirm which specific product and dose is being discussed — “semaglutide” alone isn't specific enough given how differently the forms are dosed
- Outcome actually measured: trial weight-loss percentages are group averages at a specific week number, not an individual prediction
- Where the evidence runs thin: no published trial has directly compared the tablet and injection head-to-head in the same patients, and the tablet's evidence base is newer and smaller
- The next question for your clinician: given my current health history and medications, which form's routine and absorption profile actually fits my situation?
What This Article Can't Settle For You
This is a comparison of two FDA-approved delivery methods for the same drug, not a recommendation for either one. It can't tell you whether you're a candidate for semaglutide, whether other conditions or medications change that calculation, or which form actually fits your routine. Those depend on your individual history, which is why “bring these questions to your prescriber” is the realistic next step — not a product choice to make from an article.
It's also worth being clear about what Wegovy, in either form, is not: a prescription medication requiring a clinician's ongoing oversight, not an over-the-counter supplement you start or stop on your own. If you've been researching OTC options as a different path, our look at LipoJaro and the OTC weight-management supplement category covers that separate, non-prescription category and how its evidence standards differ from an FDA-approved drug's.